Deterministic univariate sensitivity analyses were carried out to assess the uncertainties of the parameters that could affect the cost estimates of SAH and circulatory system diseases attributable to the condition in the SUS in 2019 [53]. The selection of the parameters assessed was based on the literature (prevalence and measures of effect size of diseases associated with SAH) and the presence of a variation in the data on the use of drugs in primary care (distribution of the use of antihypertensives and their respective costs).

For the prevalence of SAH in Brazil, the upper and lower limits (32.3 and 21.4%, respectively) of another Brazilian study [13] were used in order to explore the discrepancies in the literature regarding this prevalence in Brazil. The variation in prevalence affects the population using antihypertensives in primary care, the number of medical consultations and treatments by NPHWs of hypertensives in primary care and the PAR of all diseases associated with SAH. The variation in the distribution of antihypertensives in primary care was based on the 95% confidence intervals of the PNAUM data analyzed (S4 Table) and influences the total costs of antihypertensives in primary care. The costs of public pharmacy drugs were varied using the 1st to 3rd quartiles of the BPS [48] for each of the antihypertensive drugs, in order to avoid discrepant values. In the case of the PFPB, the minimum and maximum reference values reimbursed to the Brazilian states were used [49]. The cost variations of both supply sources (public pharmacies and PFPB) affect only the costs of antihypertensives in primary care. The measures of effect size were varied based on their 95% confidence intervals reported in the same articles used for the case base, affecting the PAR and consequently, the costs of circulatory system diseases attributable to SAH. The results of deterministic univariate sensitivity analyses were summarized and presented in a tornado diagram.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.